# OnCo record octreotide-lanreotide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/octreotide-lanreotide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "octreotide-lanreotide" ;
  schema:name "Somatostatin analogues (octreotide, lanreotide)"@en ;
  schema:alternateName "Octreotide"@en, "Lanreotide"@en, "Octreotide LAR"@en, "Somatostatin analogue"@en, "Sandostatin LAR, Somatuline Depot" ;
  schema:description "Monthly injections of a synthetic hormone that both quiets tumour hormone symptoms and slows tumour growth, the first treatment for most neuroendocrine tumours."@en ;
  schema:url <https://onco.cc/drugs/octreotide-lanreotide/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Octreotide> ;
  owl:sameAs <http://www.wikidata.org/entity/Q419935> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Somatostatin%20analogues> ;
  onco:status "approved" ;
  onco:modality "Peptide hormone analogue (SSTR2 agonist)" ;
  onco:approval "US 1988: Carcinoid syndrome symptoms (octreotide)", "US 2014: Unresectable GEP-NETs to improve PFS (lanreotide)" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/small-intestinal-net/>, <https://onco.cc/cancers/pancreatic-net/>, <https://onco.cc/cancers/lung-net/>, <https://onco.cc/cancers/thymoma/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/ipsen/> ;
  onco:terms <https://onco.cc/terms/carcinoid-syndrome/>, <https://onco.cc/terms/prrt-term/> ;
  onco:trials <https://onco.cc/trials/promid/>, <https://onco.cc/trials/clarinet/>, <https://onco.cc/trials/netter-1/> .